SAN
DIEGO, Feb. 23,
2015 /PRNewswire/ --Halozyme Therapeutics, Inc.
(NASDAQ: HALO) will webcast its Quarterly Update Conference Call
for the fourth quarter and full year 2014 on Monday, March 2, 2015 at 4:30 p.m. ET/1:30 p.m.
PT. Dr. Helen Torley,
President and Chief Executive Officer, will lead the call. On
the same date post-market, Halozyme will release financial results
for the fourth quarter and year-ended December 31, 2014.
The call will be webcast live through the "Investors"
section of Halozyme's corporate website and a recording will be
made available following the close of the call. To access the
webcast, please log on to www.halozyme.com approximately fifteen
minutes prior to the call to register, download and install any
necessary audio software. For those without access to the Internet,
the live call may be accessed by phone by calling (866) 710-0179
(domestic callers) or (334) 323-7224 (international callers) using
passcode 769890. A telephone replay will be available shortly after
the call by dialing (877) 919-4059 (domestic callers) or (334)
323-0140 (international callers) using replay passcode
32695691.
About Halozyme
Halozyme Therapeutics is a biotechnology company focused
on developing and commercializing novel oncology therapies that
target the tumor microenvironment. Halozyme's lead proprietary
program, our investigational drug PEGPH20, applies a unique
approach to targeting solid tumors, allowing increased access of
co-administered cancer drug therapies to the
tumor. PEGPH20 is currently in development for
metastatic pancreatic cancer and non-small cell lung cancer and has
potential across additional cancers in combination with different
types of cancer therapies. In addition to its proprietary product
portfolio, Halozyme has established value-driving partnerships with
leading pharmaceutical companies including Roche, Pfizer, Janssen
and Baxter for its drug delivery
platform, ENHANZE™, which enables biologics and small molecule
compounds that are currently administered intravenously to be
delivered subcutaneously. Halozyme is headquartered in San Diego, CA. For more information on how we
are innovating, please visit our corporate website at
www.halozyme.com.
Investor Contact:
Schond
Greenway
Halozyme
Therapeutics
858-704-8352
ir@halozyme.com
Media Contact:
Susan Neath
Francis
212-301-7182
sfrancis@w2ogroup.com
Logo -
http://photos.prnewswire.com/prnh/20100302/LA63139LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/halozyme-to-host-fourth-quarter-and-2014-year-end-financial-results-conference-call-300039824.html
SOURCE Halozyme Therapeutics, Inc.